Premium
Randomized clinical trial on the effect of a multispecies probiotic on visceroperception in hypersensitive IBS patients
Author(s) -
Ludidi S.,
Jonkers D. M.,
Koning C. J.,
Kruimel J. W.,
Mulder L.,
Vaart I. B.,
Conchillo J. M.,
Masclee A. A. M.
Publication year - 2014
Publication title -
neurogastroenterology and motility
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.489
H-Index - 105
eISSN - 1365-2982
pISSN - 1350-1925
DOI - 10.1111/nmo.12320
Subject(s) - irritable bowel syndrome , barostat , placebo , medicine , probiotic , randomized controlled trial , pathophysiology , visceral pain , gastroenterology , nociception , pathology , alternative medicine , receptor , biology , bacteria , genetics
Irritable bowel syndrome (IBS) is characterized by heterogeneous pathophysiology and low response to treatment. Up to 60% of IBS patients suffers from visceral hypersensitivity, which is associated with symptom severity and underlying pathophysiological mechanisms. Recently, positive effects of probiotics in IBS have been reported, but overall the response was modest. We performed a study in IBS patients, characterized by visceral hypersensitivity measured with the rectal barostat, aiming to assess the effect of 6 weeks of multispecies probiotic mix on visceral pain perception.